Page last updated: 2024-08-25

doripenem and Cystic Fibrosis of Pancreas

doripenem has been researched along with Cystic Fibrosis of Pancreas in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Dargahi, Z; Etemad, A; Ghasemian, E; Hashemian, M; Kaviar, VH; Lohrasbi, A; Saadh, MJ1
Abdalhamid, B; Fowler, RC; Hanson, ND; Harrison, LB; Selmecki, A1
Kemper, AL; Young, DC; Zobell, JT1
Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Maitte, A; Potel, G1
Elborn, JS; Parkins, MD1
Bergen, PJ; Bulitta, JB; Forrest, A; Jacob, J; Li, J; Nation, RL; Paterson, DL; Sidjabat, HE; Tsuji, BT1
Black, PL; Cirillo, I; Kearns, GL; Redman, R; Vaccaro, N1
Chen, Y; Garber, E; Ge, Y; Kaniga, K; Saiman, L; Wikler, MA; Zhao, Q1
Brown, SD; Traczewski, MM1

Reviews

2 review(s) available for doripenem and Cystic Fibrosis of Pancreas

ArticleYear
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
    The Yale journal of biology and medicine, 2022, Volume: 95, Issue:4

    Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa

2022
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:9

    Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cystic Fibrosis; Doripenem; Humans; Minocycline; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus aureus; Stenotrophomonas maltophilia; Tigecycline

2010

Trials

1 trial(s) available for doripenem and Cystic Fibrosis of Pancreas

ArticleYear
Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Young Adult

2012

Other Studies

6 other study(ies) available for doripenem and Cystic Fibrosis of Pancreas

ArticleYear
lptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of Pseudomonas aeruginosa.
    MicrobiologyOpen, 2019, Volume: 8, Issue:11

    Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Cell Membrane; Codon, Nonsense; Cystic Fibrosis; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Humans; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Mutation, Missense; Permeability; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Whole Genome Sequencing

2019
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
    Pediatric pulmonology, 2014, Volume: 49, Issue:3

    Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

2014
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
    The Journal of antibiotics, 2016, Volume: 69, Issue:11

    Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins

2016
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Colony Count, Microbial; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Half-Life; Humans; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections

2011
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6

    Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections

2005
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:2

    Topics: Anti-Bacterial Agents; Burkholderia cepacia; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa

2006